---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009578"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2025-03-07T23:59:59+00:00"
generated_at: "2026-05-25T02:49:29.613268+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress

## Summary
- Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.
- Net loss attributable to common shareholders $14.86M vs $13.77M in FY2023.
- Cash and equivalents $3.89M as of Dec 31, 2024, up from $1.89M a year ago.
- R&D expenses rose to $8.4M (including share-based comp); SG&A decreased to $5.4M.
- Key milestones: AI Nose Flora second-gen clinical studies H1 2025; VELDONA Japan patent and Taiwan Tanabe partnership; IRB approval for Sjögren's trial.

## SEC filing metadata
- accession: 0001493152-25-009578
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2025-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000149315225009578/0001493152-25-009578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000149315225009578/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009578
- JSON: https://secwatch.observer/filing/0001493152-25-009578.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.